Provided by Tiger Fintech (Singapore) Pte. Ltd.

KBR Inc

52.78
-0.2000-0.38%
Post-market: 52.780.00000.00%18:09 EDT
Volume:734.43K
Turnover:38.85M
Market Cap:6.85B
PE:17.72
High:53.50
Open:52.88
Low:52.62
Close:52.98
Loading ...

Why KBR Inc. (KBR) is a Top Growth Stock for the Long-Term

Zacks
·
14 Apr

KBR Inc Is Maintained at Buy by Truist Securities

Dow Jones
·
14 Apr

Luanda Refinery Upgrade, in Partnership With Eni, Expected to Be Completed by 2028 and Double Output, Executive Says

THOMSON REUTERS
·
09 Apr

Angola's Sonangol Talking to Chinese and European Banks to Fund Lobito Shortfall, Executive Says

THOMSON REUTERS
·
09 Apr

Angola's Sonangol Facing $4.8 Bln Funding Gap for New Lobito Refinery, CEO of Refining Division Says

THOMSON REUTERS
·
09 Apr

3 Market-Beating Stocks to Keep an Eye On

StockStory
·
05 Apr

KBR to Hold First Quarter Earnings Conference Call

THOMSON REUTERS
·
03 Apr

KBR to Hold First Quarter Earnings Conference Call

GlobeNewswire
·
03 Apr

Is KBR Inc. (KBR) the Best Engineering Stock to Invest in Now?

Insider Monkey
·
03 Apr

KBR Up Over 6%, on Pace for Largest Percent Increase Since February 2023 -- Data Talk

Dow Jones
·
03 Apr

3 Value Stocks Trading Below Estimated Worth For Savvy Investors

Simply Wall St.
·
28 Mar

March 2025 Stocks That May Be Priced Below Estimated Value

Simply Wall St.
·
27 Mar

Why Is KBR (KBR) Up 6.6% Since Last Earnings Report?

Zacks
·
26 Mar

March 2025 Value Equities That Could Be Trading Below Estimated Worth

Simply Wall St.
·
26 Mar

3 Stocks Estimated To Be Trading At Discounts Of Up To 47%

Simply Wall St.
·
26 Mar

Three Stocks Trading Below Estimated Value In March 2025

Simply Wall St.
·
25 Mar

3 Stocks Estimated To Be Trading Below Intrinsic Value By At Least 12.6% With Discounts Up To 48.3%

Simply Wall St.
·
20 Mar

Discover International Paper Among 3 Stocks Estimated To Be Below Fair Value

Simply Wall St.
·
19 Mar

KBR Executive Makes a Major Move with Stock Sale!

TIPRANKS
·
19 Mar

BUZZ-U.S. STOCKS ON THE MOVE- Block, KBR, Sarepta Therapeutics

Reuters
·
18 Mar